<<

agents differ in how fast they come off the D2 receptors. Implications for action

Shitij Kapur, MD, PhD; Philip Seeman, MD, PhD

Kapur Department of Psychiatry, University of Toronto; Seeman - Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ont.

Based on the presentation given by Dr. Kapur on receipt of the Canadian College of Neuropharmacology's Young Investigator Award for 1999 at the 22nd Annual Meeting of the College, Halifax, June 14, 1999.

Rationale and objective: While the blockade of dopamine D2 receptors are necessary for antipsychot- ic action, antipsychotic agents differ nearly a thousand-fold in their affinity for the D2 receptor. This affini- ty is determined by the rate at which the antipsychotic agent binds to (kn) and the rate at which it disso- ciates from (k.) the D2 receptors. The objective of this study was to determine the relationship between k.n, k,of and the affinity (K,) of antipsychotic agents for the D2 receptors, with particular reference to typi- cal and atypical antipsychotic agents. Design: The k. of several typical as well as atypical antipsychotic agents (, , , , , , , and ) was measured in vitro using the 3H-radiolabelled analogues of these drugs. The affinity of these drugs for the D2 receptor was determined by competition with 3H-raclopride in vitro. The k.n was derived from values of affinity and k,. Main outcome measures: kon, k.,f, and the K, of antipsychotic drugs. Results: The range of affinity values was similar to that conventionally accepted (0.025-155 nmol/L). The Kffvalues varied a thousand-fold from 0.002 to 3.013 min-', with relatively little variation in Kn. The rate at which antipsychotic agents come off the receptor (k.,) accounted for 99% of the variation in their affinity for the D2 receptor; differences in k., did not account for differences in affinity. Conclusions: The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor. These differences in k., may lead to functionally different kinds of dopamine blockade. Drugs with a higher k.,f will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission. Since atypical drugs show a lower affinity and a faster dissociation, a higher kff for the D2 receptor is proposed as a mechanism for "atypical" antipsychotic effect.

Justification et objectif: Meme si le blocage des recepteurs dopaminergiques D2 est necessaire pour que les neuroleptiques agissent, l'affinit6 de ceux-ci pour le recepteur D2 differe d'un ordre de grandeur

Correspondence to: Dr. Shitij Kapur, PET Centre, The Clarke Institute of Psychiatry, 250 College St., Toronto ON MST I R8; fax 416 979-4656; [email protected] Medical subject headings: antipsychotic agents; clozapine; dopamine; haloperidol; raclopride; receptors, dopamine

J Psychiatry Neurosci 2000;25(2):161-6. Submitted Nov. 23, 1999 Revised Jan. 19, 2000 Accepted Jan. 21, 2000 2000 Canadian Medical Association

1. 200 iI!,.I :I o.- i- Vo5,-oi. '0-.: ,l W'., '12.lk . 00 A41 ;-'- -j"', 400*kof I.: -: A., .. 4 Wi 311. mg, 0.4 .WIWM.

qui atteint presque le millier. Cette affinite est determinke par la vitesse i laquelle le neuroleptique se fixe (kon) aux recepteurs D2 et a la vitesse a laquelle il s'en dissocie (k.,f). L'etude visait a determiner le lien entre les fac- teurs o k,,,f et l'affinit6 (K) des neuroleptiques pour les recepteurs D2 et plus particulierement les neuroleptiques typiques et atypiques. Conception: On a mesur6 le facteur k,,, de plusieurs neuroleptiques typiques et atypiques (nemonapride, spiperone, haloperidol, chlorpromazine, raclopride, olanzapine, sertindole, clozapine et quetiapine) in vitro en utilisant les analogues radiomarques 3H de ces medicaments. L'affinit6 de ces medicaments pour le recepteur D2 a ete derivee par concurrence avec le 3H-raclopride in vitro. On a d6riv6 la valeur k.o des valeurs de l'affinite et du facteur k,,O,. Principales mesures de resultats: Facteurs ko.n ko,, et K. des neuroleptiques. Resultats: La plage des valeurs d'affinit6 ressemblait a celle qui est acceptee habituellement (0,025-155 nmol/L). Les valeurs k,, ont varie d'un facteur de l'ordre de 1000, soit de 0,002 a 3,013 min-', et la valeur k. a varie tres peu. La vitesse a laquelle les neuroleptiques se dissocient du recepteur (k,,,) explique 99 % de la variation de leur affinite pour le recepteur D2. Les differences des valeurs kn n'expliquaient pas les differences d'affinite. Conclusions: Les differences d'affinit6 des neuroleptiques sont entierement fonction de la vitesse a laquelle ils se dissocient du recepteur D2. Ces differences des valeurs k8f peuvent entrainer des types differents, sur le plan fonctionnel, de blocage de la dopamine. Les medicaments qui ont une valeur k8f plus elevee bloqueront plus rapi- dement les recepteurs et, apres le blocage, assureront un acces plus important aux pics de transmission de la dopamine. Comme les medicaments atypiques ont une affinite moindre et se dissocient plus rapidement, on pro- pose une valeur k8f plus elevee pour le recepteur D2 comme mecanisme d'effet neuroleptique (

Introduction constant, which equals k,,f/k.,, allows one to predict only the equilibrium state of the reaction. On the other All currently used antipsychotic agents bind to hand, rate constants krn and k.,f allow one to predict not dopamine D2 receptors, as assessed by their "affinity" only the equilibrium, but also how fast the drug-recep- or "potency" for the D2 receptor in vitro.',2 Discussions tor system responds to perturbations in the concentra- of the D2 effects of antipsychotic agents often use the tion of the drug or another competitor. Since the term "affinity" in a pharmacologic context and "poten- endogenous dopamine levels are not static and are cy" in a clinical context. Both of these terms usually known to show transient 10-fold increases,5 k,. and k0ff refer to the equilibrium dissociation constant, K,, or to are more relevant parameters for understanding the related term K, (which represents the equilibrium dynamic drug action. dissociation constant measured by competitive inhibi- We were interested in this issue because of the recent tion). However, Kd or K are hybrid parameters, reflect- findings that atypical are particularly ing the situation at equilibrium. These parameters are responsive to sudden increases in endogenous dopa- derived, as shown in the equation below, from 2 more mine and this may confer on them unique clinical prop- elemental parameters that characterize the dynamic erties.67 Since it is k0, and kff that determine how a drug essence of drug-receptor interaction. The binding of a responds to sudden changes in concentration and com- drug to a single receptor is said to obey the simple mass petition, we were interested in determining the k,. and action law and can be represented as below:3'4 k0ff of antipsychotic agents. In theory, a difference in either ku,, or k,,f, or both, can be responsible for changes kon in affinity, and in practice that seems to be the case. For = koff example, atropine has an affinity twice that of methyla- D+R DR; while Kd - kon koff tropinium for the cholinergic receptors; this difference in K, is driven mainly by differences in their k., with In this formulation the rate at which a drug (D) binds very similar k., values.4 On the other hand, the 100-fold to a receptor (R) is determined by the concentration of differences in affinity among 1-blockers are largely the drug, the receptor and the association rate constant, owing to differences in k., in the face of relatively simi- k,n (unit concentration-' time-', also called on-rate con- lar kr,, rates.8 Thus, it remains to be established whether stant). The rate at which the drug-receptor complex DR k.n or k0,, or both, contribute to the differential affinity dissociates is determined by the concentration of the of antipsychotics for the D) receptors. To our knowl- complex and the dissociation rate constant, k,ff (unit edge this issue has never been systematically time-1, also called off-rate constant). Kd, the equilibrium addressed.

,,0,05,r>raB;Wr q-u vt -;, .,, Anisychoti gnt n dopamne rcepors

Methods removed and rapidly filtered at various times at room temperature. The aliquots were filtered under vacuum The aim of this experiment was to determine the kon and through pre-soaked glass fibre filters (Whatman GF/B; k,ff of a series of antipsychotics and relate them to their Brandel, Gaithersburg, Md.) using a Millipore more commonly measured parameter, Ki, the inhibition (Millipore, Bedford, Mass.) filter manifold. After wash- constant. As shown in equation 1, since the 3 parame- ing the filters rapidly with 5 mL of buffer, they were ters are related, determination of any 2 permits the placed in scintillation minivials (Packard, Chicago) and delineation of the third. Of these, the k,ff and the Ki can were monitored for tritium 6 hours later in a Packard be determined with greatest accuracy; therefore we 4660 scintillation spectrometer at 55% efficiency. In a chose to measure these 2 and obtain k,n as a result.9 parallel set of tubes, nonspecific binding of the [3H]antipsychotic drug was determined in the presence Tissue of 10 pmol/L S-. Each antipsychotic was tested on 2 or 3 separate occasions. Rat brains were obtained from Pel-Freez (Rogers, Ark.). The striata were dissected in the frozen state and homog- Excess raclopride method enized in buffer (50 mmol/L TRIS-HCl, 1 mmol/L EDTA, 5 mmol/L KCl, 1.5 mmol/L CaCl2, 4 mmol/L In the presence of the [3H]antipsychotic drug, 18 mL of MgCl2, 120 mmol/L NaCl; pH 7.4) using a Brinkmann buffer was prepared containing a total of 2 mg of rat Polytron homogenizer PT-10 (Brinkmann Scientific, striatal tissue to obtain the final concentration listed Westbury, NY) (5 seconds at setting 5). Pooled tissue below. After 1 hour of incubation at room temperature, from several rats was used for the determination of kff. 0.5 mL of raclopride was added to give a final concen- tration of 10 pmol/L raclopride. Aliquots of 2 mL of the Measurement ofk,ff suspension were filtered and counted as in the dilution method. In a parallel set of tubes, nonspecific binding of Two methods are widely used to determine kff.34 Both the [3H]antipsychotic drug was done in the presence of methods rely on measuring the rate of dissociation of the 10 ,umol/L S-sulpiride. Each antipsychotic was tested radiolabelled ligand over time. In 1 method, dissociation on 2 separate occasions, the results were reliable, and is initiated by instantaneous dilution, which obviates any the averaged data are presented. reassociation (the "dilution" method).34 In the other The final concentration of each [3Hlantipsychotic method, dissociation is measured by the addition of an drug in the 2-mL pre-incubate (dilution method) and in excess of another antagonist, which competes over- the 18-mL pre-incubate (excess raclopride method) whelmingly for the same receptor and thereby obviates were identical. These concentrations, chosen to approx- any reassociation ("excess raclopride" method).9 If the imate the free molarities in the patients' spinal fluid or receptor-ligand interaction is simply a first-order reac- plasma water phase, were: [3H]nemonapride (100 tion, as characterized by equation 1, then the 2 methods Ci/mmol; New England Nuclear, Boston), 0.2 nmol/L; should give identical results. On the other hand, if rebind- [3H]spiperone (Amersham), 0.25 nmol/L; [3H]haloperi- ing or cooperativity are prominent, the interaction would dol (12 Ci/mmol; New England Nuclear), 4 nmol/L; result in a deviation from first-order kinetics, and under [3H]raclopride (79 Ci/mmol; New England Nuclear), 2 these conditions the 2 methods may give deviant results.34 nmol/L; [3H]sertindole (47 Ci/mmol; H. Lundbeck A/S, Copenhagen-Valby, Denmark), 5 nmol/L; Dilution method [3H]chlorpromazine (25 Ci/mmol; New England Nuclear), 3 nmol/L; [3H]olanzapine (81 Ci/mmol; Lilly At room temperature for 60 minutes, 1 mL of Research Laboratories, Indianapolis), 5 nmol/L; [3H]antipsychotic drug and 1 mL of rat striatal tissue [3H]clozapine (84 Ci/mmol; New England Nuclear), 10 (final = 2 mg tissue/mL) were incubated to achieve the nmol/L in the presence of 300 nmol/L clozapine; final antipsychotic concentrations listed below. After 1 [3H]quetiapine (14 Ci/mmol, custom-prepared by New hour, 16 mL of buffer was added, and the resulting mix- England Nuclear), 10 nmol/L in the presence of 200 ture was stirred to provide instantaneous dilution. nmol/L quetiapine. The time intervals over which the 8 Eight aliquots of 2 mL of the resulting suspension were measurements were distributed were different for dif-

.1. Vol.yo...1.1.25.25, AOno 2,20002' 2-W Journ4 oE Psychiatry AN& Neurosdence .1ls ferent antipsychotics and were decided on the basis of od. The results were highly correlated (Pearson's correla- preliminary experiments to provide an optimal esti- tion coefficient 0.98, p < 0.0001); therefore for further cal- mate of rate of dissociation (e.g., samples every 10 sec- culations we pooled the data from these 2 methods. onds for [3H]clozapine to every 30 minutes for The k,ff values of the available antipsychotics varied [3H]nemonapride). In each case the specific binding at almost 3 orders of magnitude, from a very slow dissoci- time zero was taken as 100%, and the effect of dilution ation constant of 0.0024 min-1 for nemonapride to 3.1 over time was plotted to obtain the time for 50% decline minw1 for quetiapine. The kn. values showed relatively in binding (t1l2). Since t112 = 0.693/k,ff, k,ff was deter- less variation, from 10.6 nmol/L-l min-' for nemon- mined from the measured t12 as 0.693/t1l2. apride to 166 nmol/Ll1min-l for olanzapine. The Ki val- ues were consistent with those reported previously. Measurement ofKi Most importantly, the Ki values were very highly pre- dicted by k,f (F1,7 = 1656, p < 0.0001) (Fig. 1), and showed The details of the method for the determination of K no significant relationship with kon values (F1,7 = 0.05, p have been presented in detail previously.2 Briefly, the = 0.829). The differences in the k., of the antipsychotics long form of the D2 receptor was stable expressed in explained 99% of the variance in their affinity for the D2 GH4Cl cells.10 Cells were collected and suspended with- receptors, whereas differences in kon do not meaningful- out washing or centrifugation and were homogenized ly relate to differences in affinity. (5 seconds at setting 5 in a Brinkmann Polytron homog- enizer PT-10) to yield approximately 200 ug/mL pro- * Quetiapine tein. [3H]raclopride, the membrane suspension and 100 / Clozapine unlabelled antipsychotic of interest were coincubated in 1.5 mL buffer with the final concentration of raclopride 10 fixed at 2 nmol/L, the receptor concentration at 10 Olanzapine * pmol/L and with varying concentrations of the anti- 2 Raclopride.* ndole psychotic for which the K, was to be determined. The Ki I 1 Chlorpromazin was calculated from the IC., concentrations using the Y FAaloperidol Cheng-Prusoff formula1" and a value of raclopride Kd of Spiperone 1.6 nmol/L, obtained as described previously.2 0.1 0 SNemonapride Results 0.01 I 0.001 0.01 0.1 1 10 (min") The detailed results are presented in Table 1 and Fig. 1. koff We did not find any significant differences (paired t-test, Fig. 1: The relationship between the equilibrium constant tdf7 = 0.925, p = 0.382) between the tl/2 determined using K,(units of concentration) and the dissociation rate con- the dilution method or using the excess radopride meth- stant k.. (units of time) for a series of antipsychotics.

| : . r S .'1-bX g ; j;< 3 11 20O'.'2 rf .sf s - o5 .r .. 0.74 Mr.;t 1~~~~~~~~~~~~~~~~~~~A 1

YI 2i i 0*17^)Wi 41.48 MM |x*-- ~ § ; .r dd.

;_ | 5. t. j..;E fi tr..LJ eSsl .ilI.AY.-.i.RV;?l-,::,:~~~~~~~~~~~~~~~~~~~~~~~~~~,',d.,t5l .: ElLJ H;' -i-V_ t "'I.,~~~~~~~~~~~~~~~~~~~~Ft 8 2 l~t. 3i.4'kfl-r.. li,.' I . -- .. - - m . .. -- ... ---, -,-- .. -t '. --. 'L. -- ...... "A I',' -. ii '. - W i. ii,

al Antipsychotic agents and dopamine receptors

Discussion agents showed a much higher affinity for the D2 recep- tor (pKi 8.87 v. 7.01; p < 0.001) than atypical antipsy- Antipsychotics vary 3 orders of magnitude in their chotic agents. The point here being that it is not the high affinity (Kd or K,) for the D2 receptor. The data presented 5-HT2 affinity but the low D2 affinity that makes an here demonstrate that the differences among antipsy- antipsychotic agent atypical. chotics are mainly owing to the rate at which they come This finding poses an interesting challenge. Anti- off the receptor. psychotic agents are used clinically in doses that are Our study is limited to the 9 antipsychotics tested. inversely proportional to their affinity. This fact This limitation was imposed by the number of radiola- remains true even in the case of the newer atypical anti- belled antipsychotics available to us. Fortunately, we psychotic agents. For example, the relative in vitro were able to access most of the labelled antipsychotics, affinities of haloperidol, , olanzapine and and they spanned a range of affinity from 0.025 nmol/L clozapine for the D2 receptor are 1.5:3:17:150 nmol/L, to 155 nmol/L and belonged to a range of different with haloperidol being most potent and clozapine the chemical classes (, , sub- least.16 As predicted by these in vitro affinities, the clin- stituted , dibenzazepines, dibenzoxaze- ical doses also share a similar relation haloperidol 2 pines), thus providing generalizability for these results. to 4 mg/d:risperidone 3 to 6 mg/d:olanzapine 10 to 20 A second limitation pertains to the extrapolation of mg/d:clozapine 250 to 450 mg/d. At first sight it may kinetic results obtained in vitro to the in vivo situation. appear that giving 100 times more of a drug with a 100- Our finding that the dilution estimates were no different times lower affinity should equate all things. Although from the excess-raclopride estimates reinforces the fact giving a proportionally higher dose of a low-affinity that the receptor homogenates and the drug behave antipsychotic agent may lead to equal occupancy at under simple bimolecular assumptions in vitro.4 How- equilibrium (since equilibrium occupancy is based only ever, in vivo the on-rate and the off-rate may be influ- on dose and affinity), the behaviour of these drugs enced by a number of conditions. The access of the drug under dynamic circumstances will still be very differ- to the receptor via blood flow or the passive-diffusion ent. This is where the differences in k,ff are crucial. We limitations may exert additional constraints on the rate of illustrate the importance of k,f by considering some association beyond that of the parameter k,n. Similarly, dynamic circumstances. local conditions such as endogenous dopamine competi- When the concentration of a drug is increased it tends tion, binding to spare receptors and rebinding after dis- toward a higher occupancy. However, the rate at which sociation, as well as the modulating effect of other recep- the drugs move toward higher occupancy differs. The tors could also alter the binding characteristics of drugs rate does not depend on affinity, but on the rate con- to the D2 receptor.12114 Although it is likely that the precise stants kon and k,ff. The time to reach this new equilibrium value of these parameters will differ in vivo, the general occupancy is inversely proportional to (kon X concentra- principle identified herein should be applicable in ViVO.12 tion + k,ff)34 in situations where there is no drop in the These findings have interesting implications for concentration of the drug due to the act of receptor-bind- understanding the differences between antipsychotic ing. By substituting values from Table 1, one finds that agents. One of the most comprehensive surveys of the 310 nmol/L of clozapine will reach a higher occupancy receptor-binding properties of antipsychotics was by equilibrium 100 times faster than 4 nmol/L haloperidol. Meltzer et al,15 who examined the binding of 37 atypical On the other hand, the rate at which a drug comes off the or presumed atypical antipsychotics on dopamine D1 receptors, either when its concentration decreases or and D2 as well as 5-HT2 receptors. This paper when there is competition from endogenous dopamine, is usually cited in support of the serotonin-dopamine is determined by kff alone. From values in Table 1, one hypothesis. But it is very important to note that Meltzer would expect 310 nmol/L of clozapine to come off the et al reported no differences in the serotonin affinities of D2 receptor nearly a 100 times faster than 4 nmol/L typical versus atypical antipsychotics (pKi values for 5- haloperidol, a finding that we have empirically demon- HT2 affinity: 8.37 v. 8.36). They also found no difference strated in vitro before (unpublished data, 1999). in D1 receptor binding either. The only major difference The higher dose of the agents with lower Kd, rather between typical and atypical antipsychotics was in their than equating the dynamic differences, actually accen- affinity for the D2 receptor. The tuates them. Since the drugs with a higher k, are given

,0X Vol. 256 nO 2.2000 Journal .1 Psychiatry & Neuroaclence :1-650165 00. .1TOUM4,m4i *....:ke.C,, ,..=4i4- {S~~a-s^.X..: s<-.glv, 0s 0, ds-D--fN in much higher doses, they speed up the rate at which References the drugs increase their occupancy as already shown. 1. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug Thus, one prediction of our finding would be that anti- doses and neuroleptic/dopamine receptors. Nature 1976;261: 717-9. psychotic agents with a lower affinity, higher k,f and a 2. Seeman P, Van Tol HH. Deriving the therapeutic concentra- faster half-time (toward the clozapine end of the spec- tions for clozapine and haloperidol: the apparent dissociation trum) will be faster in occupying receptors and will be constant of a neuroleptic at the dopamine D2 or D4 receptor changes in dopamine varies with the affinity of the competing radioligand. Eur J more responsive to endogenous Pharmacol 1995;291(2):59-66. levels than antipsychotics having a lower k., and slow- 3. Limbird L. Cell surface receptors: a short course on theory and meth- er half-time (toward the haloperidol end of the spec- ods. Boston: Kluwer Academic Publishers; 1986. trum). 4. Kenakin T. Pharmacologic analysis of drug-receptor interaction. Philadelphia: Lippincott-Raven; 1997. How these receptor kinetic differences translate into 5. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM. clinical differences is yet to be determined. But, it Regulation of transient dopamine concentration gradients in should be noted that low k,ff antipsychotic agents (e.g., the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 1992;51(1):55-64. spiperone, nemonapride, haloperidol) have all been 6. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or associated with extrapyramidal side effects (EPS) and no Parkinsonism bind more loosely than dopamine to brain D2 prolactin elevation, whereas the high k.,, antipsychotic receptors, yet occupy high levels of these receptors. Mol agents (e.g., clozapine, quetiapine) are known to be free Psychiatry 1998;3(2):123-34. 7. Seeman P, Tallerico T. Rapid release of antipsychotic drugs of EPS and prolactin elevation, essential features of an from dopamine D2 receptors: an explanation for low receptor atypical antipsychotic ageny. This is observed even occupancy and early clinical relapse upon withdrawal of cloza- though the drugs are given in doses that (based on Kd) pine or quetiapine. Am J Psychiatry 1999;156(6):876-84. 8. Affolter H, Hertel C, Jaeggi K, Portenier M, Staehelin M. (-)-S- should have equivalent effects. We propose that it is the [3H]CGP-12177 and its use to determine the rate constants of property of a high k., at the D2 receptor that makes unlabeled beta- antagonists. Proc Natl Acad Sci U S A antipsychotic agents more responsive to endogenous 1985;82(3):925-9. 9. Bellows EP, Bames DE, Csemansky JG. Estimation of haloperi- dopamine and hence less likely to give rise to side dol concentrations in rat striatum after chronic treatment. Brain effects such as EPS and prolactin elevation, which are Res Bull 1991;26(5):715-9. commonly associated with dopamine antagonism 10. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, 1999).6 Thus, a high at the D2 Frothingham L, et al. Cloning of the cDNA and gene for a (unpublished data, ko, human D2 . Proc Natl Acad Sci U S A 1989; receptor may be a mechanism for "atypical" antipsy- 86(24):9762-6. chotic effect. 11. Cheng Y, Prusof, WH, Relationship between the inhibition con- We have shown that the variation in the affinity/ stant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem potency or Kd/Ki of antipsychotic agents for D2 recep- Pharmacol 1973;22(23):3099-108. tors is almost entirely accounted for by their kff. 12. Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Antipsychotic agents differ almost a thousand-fold in Jones AK. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equi- the rate at which they come off the D2 receptor. Since it librium data in vitro. J Cereb Blood Flow Metab 1991;11(1):1-9. is k,ff that determines how quickly the antipsychotic 13. Farde L, Eriksson L, Blomquist G, Haildin C. Kinetic analysis of drug will respond to the dynamic interaction between central ["C]raclopride binding to D2-dopamine receptors stud- and in the synapse, future ied by PET-a comparison to the equilibrium analysis. J Cereb dopamine D2 receptors Blood Flow Metab 1989;9(5):696-708. research needs to explore the functional consequences 14. Votaw JR, Kessler RM, de Paulis T. Failure of the three com- of these differences between k,f. partment model to describe the in brain of a high affinity substituted . Synapse 1993; 5(3):177-90. 15. Meltzer HY, Matsubara S, Lee JC. Classification of typical and Acknowledgements atypical antipsychotic drugs on the basis of dopamine D-1, D- 2 and serotonin-2 pKi values. J Pharmacol Exp Ther 1989; We thank Dr. H.-C. Guan and Mr. Yair Lenga for excel- 251(1):238-46. 16. Schotte A, Janssen PF, Gommeren W, Luyten WH, VanGompel lent assistance. This work would not have been possible P, Lesage AS, et al. Risperidone compared with new and refer- without the support provided by the Stanley Foun- ence antipsychotic drugs: in vitro and in vivo receptor binding. dation (USA), the Medical Research Council of Canada Psychopharmacology 1996;124(1-2):57-73. and the Foundation (Canada). The financial con- 17. Kapur S, Zipursky R, Jones C, Shammi C, Remington G, EJLB Seeman P. Antipsychotic effect with only transient D2 occu- tribution of Eli Lilly Canada to this project is thankfully pancy: a clinical PET study of quetiapine. Arch Gen Psychiatry acknowledged. 1999; under review.

...